RA-308 Excimer Laser and DABRA Catheter
DeviceSee information already included in arm description
NCT Number: NCT02653456
The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the treatment of patients with lower extremity vascular disease with chronic total occlusions.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
California Heart & Vascular Clinic, El Centro, California, United States
The study is a multi center, prospective, non-randomized, open-label study conducted at a minimum of one investigational center. 50 subjects can be enrolled. Follow-up occurs at the end of the procedure in the form of an angiogram to determine if the lesion was crossed. Additional follow-up may not necessary because of the binary nature of the crossing, and also because any future follow-up would be assessing the effectiveness of adjunct therapy, e.g. balloon angioplasty. Long term results are entirely dependent on this subsequent treatment. Because the DABRA crosser only allows adjunct devices to be used, 30-day follow-up measuring the performance of the adjunct therapy might affect the physician's choice of therapy, and compromise the patient's treatment. Therefore, 30-day follow-up, which evaluates the effectiveness of the adjunct therapy, might raise ethical concerns. However, the follow-up can be done by Ankle-Brachial Index, Doppler ultrasound, auscultation, or by discussion of the level of claudication and motion pain with the patient. To evaluate the safety and efficacy of the RA-308 Excimer Laser System and DABRA Catheter for treating subjects with symptomatic infrainguinal lower extremity vascular disease with chronic total occlusions that cannot be crossed with standard guide wires, or lesions where an attempt to cross would, in the opinion of the interventionalist, result in either a subintimal path or a perforation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
See information already included in arm description
Time frame: at time of procedure
Crossing the target lesion based on angiographic analysis
Time frame: at time of procedure, up to an hour
Number of participants with no device-related major adverse events as determined by physician evaluation
Time frame: 30 days
Number of participants with target lesion revascularization as determined by physician evaluation
Time frame: 6 months
Number of participants with target lesion revascularization as determined by physician evaluation
Ra Medical Systems
Industry
A Prospective, Multi Center Pilot Study Evaluating Plaque Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Infrainguinal Lower Extremity Vascular Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05858905
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial DetailsNCT05009862
Arterial Occlusive Diseases, Arteriosclerosis
Nashville, Tennessee, United States
View Trial DetailsNCT04130737
Arterial Occlusive Diseases, Arteriosclerosis
Mesa, Arizona, United States
View Trial DetailsNCT04283565
Arterial Occlusive Diseases, Arteriosclerosis
Saint-Etienne, France
View Trial Details